J&J seeks to boost stent with DTC ads

Share this article:
With Abbott and Medtronic crowding into a market it has long split with Boston Scientific, Johnson & Johnson's Cordis is looking to raise the profile of its Cypher stent with a consumer advertising campaign—a possible first for the category.

In October, the company launched newspaper ads in The New York Times, The Wall Street Journal and USA Today.

The ads, by BBDO, show an actual-size image of the stent under headlines reading “Tennis partner,” “Hiking gear” and “Gym Equipment.”

Copy advises angina sufferers that a Cypher stent “can help get your blood pumping and your body moving once again. So you can get back to living life—playing tennis, running, working out, even sexual activity—without chest pains.”

“The goal is to help facilitate discussion between patients and physicians about coronary artery disease, the treatment options and of course, Cypher as well,” said Carol Goodrich, director of corporate comms for Cordis.

The firm is employing search engine optimization methods to boost its rankings in Yahoo and WebMD searches.

New journal ads, created by BBDO's Omnicom sibling Harrison + Star, will debut soon.
Edelman is handling PR for the effort, while interactive is being handled in-house by Johnson & Johnson's global advertising department.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.